NSE ScannerComparison · NSE · data 2026-11-01
GlaxoSmithKline Pharmaceuticals Limited vs Piramal Pharma Limited
In plain words
Size: GlaxoSmithKline Pharmaceuticals Limited is about 1.3 times the market value of Piramal Pharma Limited.
Return on equity: GlaxoSmithKline Pharmaceuticals Limited 49.1% vs Piramal Pharma Limited -4%.
Debt to equity: Piramal Pharma Limited 0.7 vs GlaxoSmithKline Pharmaceuticals Limited 0.01.
Differences in the numbers, not a recommendation of either stock.
Side by side
| GLAXO | PPLPHARMA | |
|---|---|---|
| Price | ₹2,494.3 | ₹238.91 |
| Market cap | ₹42,073 cr | ₹31,826 cr |
| P/E | 39.6 | — |
| P/B | — | 3.9 |
| ROE | 49.1% | -4.0% |
| ROCE | 52.8% | 1.3% |
| Debt / equity | 0.01 | 0.7 |
| Operating margin | 32.8% | 3.2% |
| Dividend yield | 2.30% | 0.06% |
| Sales growth, 3 years (yearly) | 5.5% | 7.8% |
| Profit growth, 3 years (yearly) | 19.3% | — |
| 1-year return | -5.9% | 17.0% |
| Revenue, last 12 months | ₹3,955 cr | ₹9,779 cr |
| Net profit, last 12 months | ₹1,068 cr | ₹-209 cr |
| Latest quarter | Jun 2026 | Sept 2026 |
| Quarter net profit | ₹237 cr | ₹6 cr |
| Quarter profit vs a year earlier | +15.7% | — |
| Promoter holding | 75.00% | 34.80% |
| Health check | Strong (6.9/10) | Weak (3.1/10) |
Common questions
Which earns a higher return on equity?
GlaxoSmithKline Pharmaceuticals Limited (49.1% against -4.0%).
Which carries more debt?
Piramal Pharma Limited has the higher debt-to-equity ratio (0.7 against 0.01).